The ATP Sensitive Potassium Channel (KATP) Is a Novel Target for Migraine Drug Development
June 2023
in “
Frontiers in Molecular Neuroscience
”
TLDR Blocking the KATP channel may help treat migraines.
The document explores ATP-sensitive potassium (KATP) channels as a novel target for migraine treatment, highlighting their role in migraine pathogenesis. Current treatments are effective for only 50-60% of patients, necessitating new approaches. KATP channel activation is a potent headache trigger, with agonists like levcromakalim inducing migraines in 100% of patients without aura. Blocking these channels could offer new therapeutic options, but existing blockers like glibenclamide are non-specific and ineffective. The study emphasizes the need for selective KATP blockers, particularly targeting the Kir6.1/SUR2B subtype, and calls for further research to assess their efficacy and safety, especially regarding cardiac implications. The research was supported by the BRIDGE Programme and Candys Foundation, with no major conflicts of interest.